Skip to main content

Articles

Page 3 of 76

  1. Hepatocellular Carcinoma (HCC) is a matter of great global public health importance; however, its current therapeutic effectiveness is deemed inadequate, and the range of therapeutic targets is limited. The ai...

    Authors: Mingang Pan, Muyu Luo, Lele Liu, Yunmeng Chen, Ziyi Cheng, Kai Wang, Luyi Huang, Ni Tang, Jianguo Qiu, Ailong Huang and Jie Xia
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:35
  2. Previous studies by our group have shown that oxidative phosphorylation (OXPHOS) is the main pathway by which pancreatic cancer stem cells (CSCs) meet their energetic requirements; therefore, OXPHOS represents...

    Authors: Sonia Alcalá, Lara Villarino, Laura Ruiz-Cañas, José R. Couceiro, Miguel Martínez-Calvo, Adrián Palencia-Campos, Diego Navarro, Pablo Cabezas-Sainz, Iker Rodriguez-Arabaolaza, Alfonso Cordero-Barreal, Lucia Trilla-Fuertes, Juan A. Rubiolo, Sandra Batres-Ramos, Mireia Vallespinos, Cristina González-Páramos, Jéssica Rodríguez…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:33
  3. Gastric cancer (GC) is associated with high mortality and heterogeneity and poses a great threat to humans. Gene therapies for the receptor tyrosine kinase RON and its spliceosomes are attracting increasing am...

    Authors: Shanshan Yu, Cheng Chen, Ming Chen, Jinxiao Liang, Kecheng Jiang, Bin Lou, Jun Lu, Xiaohua Zhu and Donghui Zhou
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:32
  4. Cadherin-17 (CDH17), a marker of differentiation in intestinal cells, binds and activates α2β1 integrin to promote cell adhesion and proliferation in colorectal cancer (CRC) metastasis. Furthermore, CDH17 asso...

    Authors: Rubén A. Bartolomé, Laura Pintado-Berninches, Ángela Martín-Regalado, Javier Robles, Tania Calvo-López, Marina Ortega-Zapero, Celia Llorente-Sáez, Issam Boukich, María Jesús Fernandez-Aceñero and J. Ignacio Casal
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:31
  5. MEK inhibitors (MEKi) were shown to be clinically insufficiently effective in patients suffering from BRAF wild-type (BRAF WT) melanoma, even if the MAPK pathway was constitutively activated due to mutations i...

    Authors: Francisco Meraz-Torres, Heike Niessner, Sarah Plöger, Simon Riel, Barbara Schörg, Nicolas Casadei, Manfred Kneilling, Martin Schaller, Lukas Flatz, Boris Macek, Thomas Eigentler, Olaf Rieß, Claus Garbe, Teresa Amaral and Tobias Sinnberg
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:30
  6. The VHL-HIF pathway and lipid droplet accumulation are the main characteristics of clear cell renal cell carcinoma (ccRCC). However, the connection between the two features is largely unknown.

    Authors: Haibing Xiao, Yan Qu, Haolin Li, Yi Zhang, Mintian Fei, Chaozhao Liang, Hongmei Yang and Xiaoping Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:29
  7. Glioblastoma (GBM) is the most common malignant tumor of the central nervous system. It is an aggressive tumor characterized by rapid proliferation, diffuse tumor morphology, and poor prognosis. Unfortunately,...

    Authors: Jie Li, Bin Zhang, Zishan Feng, Dandan An, Zhiyuan Zhou, Chao Wan, Yan Hu, Yajie Sun, Yijun Wang, Xixi Liu, Wenwen Wei, Xiao Yang, Jingshu Meng, Mengjie Che, Yuhan Sheng, Bian Wu…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:28
  8. Peritoneal metastasis, which accounts for 85% of all epithelial ovarian carcinoma (EOC) metastases, is a multistep process that requires the establishment of adhesive interactions between cancer cells and the ...

    Authors: Michela Terri, Pilar Sandoval, Giulio Bontempi, Claudia Montaldo, Henar Tomero-Sanz, Valeria de Turris, Flavia Trionfetti, Lucía Pascual-Antón, Irene Clares-Pedrero, Cecilia Battistelli, Sergio Valente, Clemens Zwergel, Antonello Mai, Laura Rosanò, Miguel Ángel del Pozo, Miguel Sánchez-Álvarez…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:27
  9. Authors: Wei Wei, Zhong-Yuan Zhang, Bin Shi, Yike Cai, Hou-Shun Zhang, Chun-Lei Sun, Yun-Fei Fei, Wen Zhong, Shuang Zhang, Chen Wang, Bing He, Guan-Min Jiang and Hao Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:26

    The original article was published in Journal of Experimental & Clinical Cancer Research 2023 42:151

  10. Extensive local invasion of glioblastoma (GBM) cells within the central nervous system (CNS) is one factor that severely limits current treatments. The aim of this study was to uncover genes involved in the in...

    Authors: Zhiyi Xue, Yan Zhang, Ruiqi Zhao, Xiaofei Liu, Konrad Grützmann, Barbara Klink, Xun Zhang, Shuai Wang, Wenbo Zhao, Yanfei Sun, Mingzhi Han, Xu Wang, Yaotian Hu, Xuemeng Liu, Ning Yang, Chen Qiu…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:25
  11. Non-muscle-invasive bladder cancer (NMIBC) is treated with transurethral resection of bladder tumor (TURBT) followed by intravesical instillation of chemotherapy or Bacillus Calmette–Guérin therapy. However, t...

    Authors: Fangming Wang, Gang Zhang, Tianli Xu, Jianlin Ma, Jing Wang, Shuai Liu, Yuzhe Tang, Song Jin, Jianxing Li and Nianzeng Xing
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:24
  12. Triple-negative breast cancer is a complex breast malignancy subtype characterized by poor prognosis. The pursuit of effective therapeutic approaches for this subtype is considerably challenging. Notably, rece...

    Authors: Zihan Xi, Haohao Huang, Jin Hu, Yuanhang Yu, Xianxiong Ma, Ming Xu, Jie Ming, Lei Li, Hui Zhang, Hengyu Chen and Tao Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:22
  13. Extracellular vesicles (EVs) participate in cancer development via cell-to-cell communication. Long non-coding RNAs (lncRNAs), one component of EVs, can play an essential role in non-small-cell lung cancer (NS...

    Authors: Xinyi Ma, Zhenhua Chen, Wei Chen, Ziyuan Chen, Yue Shang, Yikai Zhao, Leyi Li, Chengwei Zhou, Jinxian He and Xiaodan Meng
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:20
  14. Ferroptosis, a novel form of cell death triggered by iron-dependent phospholipid peroxidation, presents significant therapeutic potential across diverse cancer types. Central to cellular metabolism, the metabo...

    Authors: Yuze Hua, Sen Yang, Yalu Zhang, Jiayi Li, Mengyi Wang, Palashate Yeerkenbieke, Quan Liao and Qiaofei Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:19
  15. Medulloblastoma (MB) patients with MYC oncogene amplification or overexpression exhibit extremely poor prognoses and therapy resistance. However, MYC itself has been one of the most challenging targets for can...

    Authors: Don W. Coulter, Yashpal S. Chhonker, Devendra Kumar, Varun Kesherwani, Wafaa N. Aldhafiri, Erin M. McIntyre, Gracey Alexander, Sutapa Ray, Shantaram S. Joshi, Rongshi Li, Daryl J. Murry and Nagendra K. Chaturvedi
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:18
  16. Prohibitin 2 (PHB2) exhibits opposite functions of promoting or inhibiting tumour across various cancer types. In this study, we aim to investigate its functions and underlying mechanisms in the context of gas...

    Authors: Liang Xu, Wanying Xiang, Jiezhen Yang, Jing Gao, Xinyue Wang, Li Meng, Kaihong Ye, Xiao Hong Zhao, Xu Dong Zhang, Lei Jin and Yan Ye
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:17
  17. As a novel necrosis manner, ferroptosis has been increasingly reported to play a role in tumor progression and treatment, however, the specific mechanisms underlying its development in prostate cancer remain u...

    Authors: Yu Zhang, Zhenlin Huang, Keqiang Li, Guoqing Xie, Yuankang Feng, Zihao Wang, Ningyang Li, Ruoyang Liu, Yinghui Ding, Jun Wang, Jinjian Yang and Zhankui Jia
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:16
  18. New drugs to tackle the next pathway or mutation fueling cancer are constantly proposed, but 97% of them are doomed to fail in clinical trials, largely because they are identified by cellular or in silico scre...

    Authors: Ambra Cappelletto, Edoardo Alfì, Nina Volf, Thi Van Anh Vu, Francesca Bortolotti, Giulio Ciucci, Simone Vodret, Marco Fantuz, Martina Perin, Andrea Colliva, Giacomo Rozzi, Matilde Rossi, Giulia Ruozi, Lorena Zentilin, Roman Vuerich, Daniele Borin…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:15
  19. Metastasis has emerged as the major reason of treatment failure and mortality in patients with nasopharyngeal carcinoma (NPC). Growing evidence links abnormal DNA methylation to the initiation and progression ...

    Authors: Shi-Qing Zhou, Ping Feng, Ming-Liang Ye, Sheng-Yan Huang, Shi-Wei He, Xun-Hua Zhu, Jun Chen, Qun Zhang and Ying-Qing Li
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:14
  20. Inflammation in the eye is often associated with aggravated ocular diseases such as uveal melanoma (UM). Poor prognosis of UM is generally associated with high potential of metastatic liver dissemination. A st...

    Authors: Shi Yong Neo, Mariana M. S. Oliveira, Le Tong, Yi Chen, Ziqing Chen, Sonia Cismas, Nutsa Burduli, Anna Malmerfelt, Joey Kay Hui Teo, Kong-Peng Lam, Evren Alici, Leonard Girnita, Arnika K. Wagner, Lisa S. Westerberg and Andreas Lundqvist
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:13
  21. Targeted therapies, including small molecule inhibitors directed against aberrant kinase signaling and chromatin regulators, are emerging treatment options for high-grade gliomas (HGG). However, when translati...

    Authors: Lea M. Stitzlein, Jack T. Adams, Erin N. Stitzlein, Richard W. Dudley and Joya Chandra
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:12
  22. Radiotherapy-activated NBTXR3 (NBTXR3 + RT) has demonstrated superior efficacy in cancer cell destruction and tumor growth control, compared to radiotherapy (RT), in preclinical and clinical settings. Previous...

    Authors: Jordan Da Silva, Célia Bienassis, Peter Schmitt, Céline Berjaud, Mickael Guedj and Sébastien Paris
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:11
  23. The variability in responses to neoadjuvant treatment with anti-HER2 antibodies prompts to personalized clinical management and the development of innovative treatment strategies. Tumor-infiltrating Natural Ki...

    Authors: Sara Santana-Hernández, Jesús Suarez-Olmos, Sonia Servitja, Pau Berenguer-Molins, Marcel Costa-Garcia, Laura Comerma, Anna Rea, Julia Perera-Bel, Silvia Menendez, Oriol Arpí, Begoña Bermejo, María Teresa Martínez, Juan Miguel Cejalvo, Iñaki Comino-Méndez, Javier Pascual, Emilio Alba…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:10
  24. Podoplanin (PDPN) is a highly conserved, mucin-type protein specific to the lymphatic system. Overexpression of PDPN is associated with the progression of various solid tumors, and plays an important roles in ...

    Authors: Chunyan Feng, Albert Yu, Zhongfu Wang, Kun Wang, Jiawei Chen, Yaojiong Wu, Ting Deng, Huaqing Chen, Yibo Hou, Shaohua Ma, Xiaoyong Dai and Laiqiang Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:9
  25. Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. The tumor immune microenvironment (TIME) formed by interactions among cancer cells, immune cells, cancer-associated fibroblasts (...

    Authors: Wenyu Luo, Ti Wen and Xiujuan Qu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:8

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2024 43:21

  26. Chemoresistance presents a significant obstacle in the treatment of colorectal cancer (CRC), yet the molecular basis underlying CRC chemoresistance remains poorly understood, impeding the development of new th...

    Authors: Xiaojian Zhu, Changxue Li, Yunfei Gao, Qingyuan Zhang, Tao Wang, Huaixiang Zhou, Fanqin Bu, Jia Chen, Xinjun Mao, Yulong He, Kaiming Wu, Ningning Li and Hongliang Luo
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:7
  27. About 10% of NSCLCs are mutated in KRAS and impaired in STK11/LKB1, a genetic background associated with poor prognosis, caused by an increase in metastatic burden and resistance to standard therapy. LKB1 is a pr...

    Authors: Gloriana Ndembe, Ilenia Intini, Massimo Moro, Chiara Grasselli, Andrea Panfili, Nicolò Panini, Augusto Bleve, Mario Occhipinti, Cristina Borzi, Marina Chiara Garassino, Mirko Marabese, Simone Canesi, Eugenio Scanziani, Gabriella Sozzi, Massimo Broggini and Monica Ganzinelli
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:6
  28. Tumor-associated inflammation suggests that anti-inflammatory medication could be beneficial in cancer therapy. Loratadine, an antihistamine, has demonstrated improved survival in certain cancers. However, the...

    Authors: Xiwen Liu, Ran Zhong, Jiaxing Huang, Zisheng Chen, Haoxiang Xu, Lixuan Lin, Qi Cai, Miao He, Shen Lao, Hongsheng Deng, Caichen Li, Jianfu Li, Yongmei Zheng, Xiaoyan Liu, Riqi Zeng, Jianxing He…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:5
  29. Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of cancer and the chemotherapies such as gemcitabine/nab-paclitaxel are confronted with intrinsic or acquired resistance. The aim of this s...

    Authors: Cecilia Bergonzini, Alessandro Gregori, Tessa M. S. Hagens, Vera E. van der Noord, Bob van de Water, Annelien J. M. Zweemer, Bircan Coban, Mjriam Capula, Giulia Mantini, Asia Botto, Francesco Finamore, Ingrid Garajova, Liam A. McDonnell, Thomas Schmidt, Elisa Giovannetti and Erik H. J. Danen
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:4
  30. Lung cancer is a malignant tumor with the highest mortality worldwide. Abnormalities in the ubiquitin proteasome system are considered to be contributed to lung cancer progression with deleterious effects. DDB...

    Authors: Shan Wei, Jing Xing, Jia Chen, Liping Chen, Jiapei Lv, Xiaofei Chen, Tang Li, Tao Yu, Huaying Wang, Kai Wang and Wanjun Yu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:3
  31. Cisplatin (CDDP)-based chemotherapy is a standard first-line treatment for metastatic bladder cancer (BCa) patients, and chemoresistance remains a major challenge in clinical practice. Circular RNAs (circRNAs)...

    Authors: Wenjie Wei, Kan Liu, Xing Huang, Shuo Tian, Hanfeng Wang, Chi Zhang, Jiali Ye, Yuhao Dong, Ziyan An, Xin Ma, Baojun Wang, Yan Huang and Xu Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:2
  32. Ceramide metabolism is crucial in the progress of brain metastasis (BM). However, it remains unexplored whether targeting ceramide metabolism may arrest BM.

    Authors: Ying Lin, Yun Wu, Qiangzu Zhang, Xunwei Tu, Sufang Chen, Junfan Pan, Nengluan Xu, Ming Lin, Peiwei She, Gang Niu, Yusheng Chen and Hongru Li
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:1

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2024 43:37

  33. In recent years, research focused on the multifaceted landscape and functions of cancer-associated fibroblasts (CAFs) aimed to reveal their heterogeneity and identify commonalities across diverse tumors for mo...

    Authors: Roberta Melchionna, Paola Trono, Anna Di Carlo, Francesca Di Modugno and Paola Nisticò
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:347
  34. Atypical teratoid rhabdoid tumors (ATRT) is a rare but aggressive malignancy in the central nervous system, predominantly occurring in early childhood. Despite aggressive treatment, the prognosis of ATRT patie...

    Authors: Le Hien Giang, Kuo-Sheng Wu, Wei-Chung Lee, Shing-Shung Chu, Anh Duy Do, Chun A. Changou, Huy Minh Tran, Tsung-Han Hsieh, Hsin-Hung Chen, Chia-Ling Hsieh, Shian-Ying Sung, Alice L. Yu, Yun Yen, Tai-Tong Wong and Che-Chang Chang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:346
  35. Authors: Yuanshan Yao, Chunji Chen, Jing Wang, Haojie Xuan, Xiuxiu Chen, Zheng Li, Fuzhi Yang, Bin Wang, Siyun Lin, Saitian Li, Dongfang Tang, Libao Gong and Wen Gao
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:345

    The original article was published in Journal of Experimental & Clinical Cancer Research 2023 42:330

  36. Research has indicated that long-term sleep deprivation can lead to immune dysfunction and participate in the occurance and progression of tumors. However, the relationship between sleep deprivation and colon ...

    Authors: Haijun Bao, Zuojie Peng, Xukai Cheng, Chenxing Jian, Xianguo Li, Yongping Shi, Wenzhong Zhu, Yuan Hu, Mi Jiang, Jia Song, Feifei Fang, Jinhuang Chen and Xiaogang Shu
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:344
  37. In vitro models are necessary to study the pathophysiology of the disease and the development of effective, tailored treatment methods owing to the complexity and heterogeneity of breast cancer and the large p...

    Authors: Anamitra Bhattacharya, Kamare Alam, Nakka Sharmila Roy, Kulwinder Kaur, Santanu Kaity, Velayutham Ravichandiran and Subhadeep Roy
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:343
  38. More than 90% of the mortality of triple-negative breast cancer (TNBC) patients is attributed to cancer metastasis with organotropism. The lung is a frequent site of TNBC metastasis. However, the precise molec...

    Authors: Shaojie Cheng, Xueying Wan, Liping Yang, Yilu Qin, Shanchun Chen, Yongcan Liu, Yan Sun, Yuxiang Qiu, Luyi Huang, Qizhong Qin, Xiaojiang Cui, Mingjun Wu and Manran Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:342
  39. Chimeric antigen receptor (CAR) T-cells are a promising approach in cancer immunotherapy, particularly for treating hematologic malignancies. Yet, their effectiveness is limited when tackling solid tumors, whe...

    Authors: Liliana R. Loureiro, Lydia Hoffmann, Christin Neuber, Luise Rupp, Claudia Arndt, Alexandra Kegler, Manja Kubeil, Christoph E. Hagemeyer, Holger Stephan, Marc Schmitz, Anja Feldmann and Michael Bachmann
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:341
  40. Cancer cells undergo cellular adaptation through metabolic reprogramming to sustain survival and rapid growth under various stress conditions. However, how brain tumors modulate their metabolic flexibility in ...

    Authors: Hye Jin Yun, Min Li, Dong Guo, So Mi Jeon, Su Hwan Park, Je Sun Lim, Su Bin Lee, Rui Liu, Linyong Du, Seok-Ho Kim, Tae Hwan Shin, Seong-il Eyun, Yun-Yong Park, Zhimin Lu and Jong-Ho Lee
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:340
  41. Within the tumor immune microenvironment (TME), tumor-associated macrophages (TAMs) are crucial in modulating polarization states to influence cancer development through metabolic reprogramming. While long non...

    Authors: Jiayu Lin, Yihao Liu, Pengyi Liu, Wenxin Qi, Jia Liu, Xingfeng He, Qian Liu, Zehua Liu, Jingxin Yin, Jiewei Lin, Haili Bao and Jianhong Lin
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:339
  42. Oncogenic KRAS mutation, the most frequent mutation in non-small cell lung cancer (NSCLC), is an aggressiveness risk factor and leads to the metabolic reprogramming of cancer cells by promoting glucose, glutamine...

    Authors: Dasom Kim, Dongwha Min, Joohee Kim, Min Jung Kim, Yerim Seo, Byung Hwa Jung, Seung‑Hae Kwon, Hyunju Ro, Seoee Lee, Jason K. Sa and Ji-Yun Lee
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:338
  43. Myeloid cells (granulocytes and monocytes/macrophages) play an important role in neuroblastoma. By inducing a complex immunosuppressive network, myeloid cells pose a challenge for the adaptive immune system to...

    Authors: Marjolein C. Stip, Loes Teeuwen, Miranda P. Dierselhuis, Jeanette H. W. Leusen and Daniëlle Krijgsman
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:337
  44. Cancer-endothelial interplay is crucial for tumor behavior, yet the molecular mechanisms involved are largely unknown. Interleukin(IL)-30, which is expressed as a membrane-anchored cytokine by human prostate c...

    Authors: Stefania Livia Ciummo, Carlo Sorrentino, Cristiano Fieni and Emma Di Carlo
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:336
  45. Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignant tumors globally. Understanding the molecular basis of tumor progression and drug resistance can offer innovative strategies to ...

    Authors: Li Cui, Ye Lu, Jiarong Zheng, Bing Guo and Xinyuan Zhao
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:335
  46. With the advancements in bioinformatic technology, an increasing number of circular RNAs (circRNAs) have been discovered and their crucial roles in the development and progression of various malignancies have ...

    Authors: Zhenzhou Chen, Yidan Li, Kuan He, Jianguo Yang, Qican Deng, Yajun Chen and Zhongxue Fu
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:334
  47. In addition to anti-PD(L)1, anti-CTLA-4 and anti-LAG-3, novel immune checkpoint proteins (ICP)-targeted antibodies have recently failed to demonstrate significant efficacy in clinical trials. In these trials, ...

    Authors: Delphine Bredel, Edi Tihic, Séverine Mouraud, François-Xavier Danlos, Sandrine Susini, Marine Aglave, Alexia Alfaro, Chifaou Mohamed-Djalim, Mathieu Rouanne, Héloise Halse, Amélie Bigorgne, Lambros Tselikas, Stéphane Dalle, Dana M. Hartl, Eric Baudin, Catherine Guettier…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:333
  48. Authors: Sang-Yun Lee, Hyeong Jun Cho, Jimin Choi, Bosung Ku, Seok Whan Moon, Mi Hyoung Moon, Kyung Soo Kim, Kwanyong Hyun, Tae-Jung Kim, Yeoun Eun Sung, Yongki Hwang, Eunyoung Lee, Dong Hyuck Ahn, Joon Young Choi, Jeong Uk Lim, Chan Kwon Park…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:332

    The original article was published in Journal of Experimental & Clinical Cancer Research 2023 42:309

Annual Journal Metrics

  • 2022 Citation Impact
    11.3 - 2-year Impact Factor
    11.5 - 5-year Impact Factor
    1.870 - SNIP (Source Normalized Impact per Paper)
    2.413 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    100 days submission to accept (Median)

    2023 Usage 
    3,003,080 downloads
    3,022 Altmetric mentions